Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | DRD1 | P21728 | 8/20 | 0.54 |
| ▸ | DRD2 | P14416 | 6/20 | 0.54 |
| ▸ | F3 | P13726 | 4/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD5 | P21918 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP2 | O95551 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14886118 | 1.00 | HTR1A (0.81) | HTR1ACYP3A4DRD1DRD2F3 | |
| Caryachine SCHEMBL6376741 | 0.89 | HTR1A (1.00) | HTR1ACYP3A4DRD1DRD2F3 | |
| Caryachine SCHEMBL29350783 | 0.89 | HTR1A (1.00) | HTR1ACYP3A4DRD1DRD2F3 | |
| Escholtzine SCHEMBL29406066 | 0.88 | HTR1A (1.00) | HTR1ACYP3A4DRD1DRD2ADRA1A | |
| Escholtzine SCHEMBL29692675 | 0.88 | HTR1A (1.00) | HTR1ACYP3A4DRD1DRD2ADRA1A | |
| SCHEMBL14883441 | 0.87 | HTR1A (0.74) | HTR1ACYP3A4DRD1DRD2F3 | |
| Argemonine SCHEMBL30435899 | 0.86 | HTR1A (0.58) | HTR1ACYP3A4DRD1DRD2F3 | |
| Argemonine SCHEMBL3865650 | 0.86 | HTR1A (0.58) | HTR1ACYP3A4DRD1DRD2F3 | |
| SCHEMBL18625049 | 0.82 | HTR1A (0.56) | HTR1ACYP3A4DRD1DRD2KMT2A | |
| SCHEMBL18878360 | 0.82 | HTR1A (0.56) | HTR1ACYP3A4DRD1DRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007009462-A2 | TREATMENT OF MIGRAINE AND HEADACHES | REGION HOVEDSTADEN V/GLOSTRUP HOSPITAL (DK) | 2007-01-25 | — | — | WO | claimed |
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | ANTHEIA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12497638-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250137021-A1 | METHODS OF PRODUCING NOR-OPIOID AND NAL-OPIOID BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2025-05-01 | — | — | US | disclosed |
| EP-3221461-B1 | NOSCAPINOID-PRODUCING MICROBES AND METHODS OF MAKING AND USING THE SAME | UNIV LELAND STANFORD JUNIOR (US) | 2025-01-01 | — | — | EP | disclosed |
| US-12180525-B2 | Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240218408-A1 | Methods of Producing Epimerases and Benzylisoquinoline Alkaloids | HERCULES CAPITAL, INC., AS AGENT | 2024-07-04 | — | — | US | disclosed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | disclosed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2010053584-A2 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2007009462-A2 | TREATMENT OF MIGRAINE AND HEADACHES | REGION HOVEDSTADEN V/GLOSTRUP HOSPITAL (DK) | 2007-01-25 | — | — | WO | disclosed |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2006-06-22 | — | — | US | disclosed |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-07-21 | — | — | US | disclosed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| CN-1176909-C | Application of thaliporphine or its derivative in treating heart disease and its preparation method | ��ʱ��ѧ��ҩ�ɷ�����˾ | 2004-11-24 | — | — | CN | disclosed |
| EP-1311486-A4 | USES OF THALIPORPHINE OR ITS DERIVATIVES IN TREATMENT OF CARDIAC DISEASES AND PREPARATION OF SAME | LOTUS PHARMACEUTICAL CO LTD (TW) | 2004-03-31 | — | — | EP | disclosed |
| CN-1429212-A | Application of thaliporphine or its derivative in treating heart disease and its preparation method | MEISHI CHEMICAL PHARMACEUTICAL (CN) | 2003-07-09 | — | — | CN | disclosed |
| EP-1311486-A1 | USES OF THALIPORPHINE OR ITS DERIVATIVES IN TREATMENT OF CARDIAC DISEASES AND PREPARATION OF SAME | Lotus Pharmaceutical Co., Ltd. (TW) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016325-A1 | USES OF THALIPORPHINE OR ITS DERIVATIVES IN TREATMENT OF CARDIAC DISEASES AND PREPARATION OF SAME | SU MINGJAI (CN) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | HTR1A 1293/4885CYP3A4 3262/4885DRD1 4452/4885 |
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | OPRK1, OPRM1, OPRD1 | HTR1A 94/4885CYP3A4 13/4885DRD1 532/4885 |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PTGS2, PTGES2, PTGS1 | HTR1A 583/4885CYP3A4 2436/4885DRD1 3970/4885 |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PTGS2, PTGS1, PTGIS | HTR1A 503/4885CYP3A4 3681/4885DRD1 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.